Vimarsana
Biggest News Aggregation in the World

Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today

Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData - Vimarsana News

Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData

Published: February 20, 2024

Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData

Source: investorideas.com
Related Topics:
Alison LabyaDaiichi SankyoLilly MounjaroNovo Nordisk WegovyBristol Myers SquibbUs SenateVertex PharmaceuticalsRegeneron PharmaceuticalsNovo NordiskGlobaldata Pharmaceutical Intelligence CenterGlobaldata Drugs Database Pharma Intelligence CenterInflation Reduction ActBusiness Fundamentals AnalystDrugs Database Pharma IntelligenceMyers SquibbPharmaceutical IntelligenceInvestor IdeasGlobal Biopharmaceutical Companies
VIS-954 by Visterra for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval - Vimarsana News

VIS-954 by Visterra for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval

Published: February 19, 2024

VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis).

Source: pharmaceutical-technology.com
Related Topics:
United KingdomUnited StatesGlobaldata Pharmaceutical Intelligence CenterOtsuka Holdings Co LtdPharmaceutical Intelligence
Botensilimab by Agenus for Cervical Cancer: Likelihood of Approval - Vimarsana News

Botensilimab by Agenus for Cervical Cancer: Likelihood of Approval

Published: February 9, 2024

Botensilimab is under clinical development by Agenus and currently in Phase I for Cervical Cancer.

Source: pharmaceutical-technology.com
Related Topics:
United StatesGlobaldata Pharmaceutical Intelligence CenterCervical CancerPhase Transition Success Rate ModelHeat Shock ProteinPharmaceutical Intelligence
Zalifrelimab by Agenus for Cervical Cancer: Likelihood of Approval - Vimarsana News

Zalifrelimab by Agenus for Cervical Cancer: Likelihood of Approval

Published: February 9, 2024

Zalifrelimab is under clinical development by Agenus and currently in Phase II for Cervical Cancer.

Source: pharmaceutical-technology.com
Related Topics:
United StatesGlobaldata Pharmaceutical Intelligence CenterCervical CancerPhase Transition Success Rate ModelHeat Shock ProteinPharmaceutical Intelligence
Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval - Vimarsana News

Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval

Published: February 9, 2024

Botensilimab is under clinical development by Agenus and currently in Phase I for Ovarian Cancer.

Source: pharmaceutical-technology.com
Related Topics:
United StatesGlobaldata Pharmaceutical Intelligence CenterOvarian CancerPhase Transition Success Rate ModelHeat Shock ProteinPharmaceutical Intelligence